Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Daratumumab”

350 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 350 results

Early research (Phase 1)Ended earlyNCT04045028
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
Genentech, Inc. 41
Not applicableNot Yet RecruitingNCT07015021
What this trial is testing

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Who this might be right for
Multiple MyelomaCarfilzomibDaratumumab+1 more
The First Affiliated Hospital of Soochow University 72
Testing effectiveness (Phase 2)Study completedNCT02963493
What this trial is testing

Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Oncopeptides AB 157
Testing effectiveness (Phase 2)Study completedNCT02316106
What this trial is testing

Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 123
Testing effectiveness (Phase 2)Ended earlyNCT03367819
What this trial is testing

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Who this might be right for
Prostate CancerNon-small Cell Lung Cancer
Sanofi 44
Testing effectiveness (Phase 2)WithdrawnNCT03221634
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC
Testing effectiveness (Phase 2)WithdrawnNCT05486481
What this trial is testing

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

Who this might be right for
AL AmyloidosisLight Chain (AL) AmyloidosisSystemic Light Chain Disease
Alfred Chung, MD
Testing effectiveness (Phase 2)Active Not RecruitingNCT03236428
What this trial is testing

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Who this might be right for
Monoclonal GammopathySmoldering Multiple Myeloma
Dana-Farber Cancer Institute 42
Large-scale testing (Phase 3)Study completedNCT02252172
What this trial is testing

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 737
Testing effectiveness (Phase 2)UnknownNCT04065308
What this trial is testing

Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma

Who this might be right for
Multiple Myeloma in RelapsePlasmacytomaDaratumumab
Seoul National University Hospital 33
Large-scale testing (Phase 3)Not Yet RecruitingNCT07072585
What this trial is testing

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Who this might be right for
Stage II T Lymphoblastic Leukemia/LymphomaStage III T Lymphoblastic Leukemia/LymphomaStage IV T Lymphoblastic Leukemia/Lymphoma+2 more
Children's Oncology Group 1,708
Testing effectiveness (Phase 2)WithdrawnNCT03035357
What this trial is testing

Neoadjuvant Listeria or Daratumumab in Prostate Cancer

Who this might be right for
Malignant Neoplasms of Male Genital OrgansProstate Cancer
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT05182073
What this trial is testing

FT576 in Subjects With Multiple Myeloma

Who this might be right for
Multiple MyelomaMyeloma
Fate Therapeutics 31
Early research (Phase 1)Looking for participantsNCT06287944
What this trial is testing

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
City of Hope Medical Center 15
Early research (Phase 1)WithdrawnNCT04088903
What this trial is testing

Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation

Who this might be right for
AllosensitizationHeart Transplant Failure and Rejection
Ronald Witteles
Testing effectiveness (Phase 2)Active Not RecruitingNCT04113018
What this trial is testing

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Wake Forest University Health Sciences 39
Post-approval studies (Phase 4)Active Not RecruitingNCT03829371
What this trial is testing

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

Who this might be right for
Multiple Myeloma
University of Turin, Italy 450
Early research (Phase 1)Ended earlyNCT04956302
What this trial is testing

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Abdullah Khan 1
Testing effectiveness (Phase 2)Study completedNCT03194867
What this trial is testing

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Who this might be right for
Plasma Cell Myeloma
Sanofi 109
Testing effectiveness (Phase 2)Looking for participantsNCT07063199
What this trial is testing

Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)

Who this might be right for
Immune ThrombocytopeniaTreatment
Institute of Hematology & Blood Diseases Hospital, China 30
Load More Results